Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DG

Written by Ruchika Sharma Published On 2021-06-26T12:09:55+05:30 | Updated On 26 Jun 2021 12:09 PM IST

Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DG

Karnataka: Shilpa Medicare Limited, has recently announced that the company has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country.

"Shilpa Medicare Limited is only the second company in India to have entered into similar arrangement with DRDO," the company said in a filing.

Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine, the drugmaker added.

Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Read also: Shilpa Medicare gets USFDA nod for psoriatic arthritis drug Apremilast

shilpa medicareshilpa medicare newscovid drugdrdo2-dgdcgicoronavirus

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751